Physician profile

Warren Groff

Family Medicine · Callahan, FL

NPI 1558348110

$8,127.64

in general payments reported to CMS, 2019-2025

41 companies · $183 in 2025

The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,024.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,402.42 2019-2023 Breztri, Farxiga
Pfizer INC. $1,101.04 2019-2023
Lilly USA, LLC $680.41 2019-2023 Mounjaro, Jardiance
Edwards Lifesciences Corporation $661.92 2021-2025 Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia
Novo Nordisk INC $583.59 2019-2023 Ozempic, Rybelsus
Glaxosmithkline, LLC. $314.08 2019-2023 Trelegy Ellipta, Shingrix, Arexvy
Amarin Pharma, INC. $296.41 2019-2021
Abbott Laboratories $264.41 2021-2024 Freestyle Libre 3, Freestyle Libre 2
Merck Sharp & Dohme LLC $263.79 2019-2023 Verquvo, Belsomra
Bayer Healthcare Pharmaceuticals INC. $251.62 2021-2023
Eisai INC. $240.23 2020-2022
Boehringer Ingelheim Pharmaceuticals, INC. $215.31 2019-2023 Jardiance, Ofev
Abbvie INC. $205.64 2021-2023
Sanofi-Aventis U.S. LLC $186.69 2019-2022
Horizon Therapeutics Plc $157.96 2020-2023 Krystexxa
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $146.76 2020-2024 Bionic Navigator
Astellas Pharma US INC $136.54 2019-2023 Veozah
Mannkind Corporation $73.80 2023 Afrezza
Vivus LLC $73.00 2019-2023 Qsymia
Takeda Pharmaceuticals U.S.A., INC. $71.63 2019-2022
Supernus Pharmaceuticals, INC. $70.42 2019
Biohaven Pharmaceutical Holding Company LTD. $66.05 2022
Allergan, INC. $62.08 2019-2020
Sanofi Pasteur INC. $56.23 2020-2023
Avanir Pharmaceuticals, INC. $53.64 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $49.64 2022-2023 Xifaxan
Novartis Pharmaceuticals Corporation $49.50 2021-2022
Inspire Medical Systems, INC. $47.86 2025 Inspire
Janssen Pharmaceuticals, INC $47.21 2020-2022
Biohaven Pharmaceuticals, INC. $44.94 2020-2021
E.R. Squibb & Sons, L.L.C. $39.11 2021-2023 Eliquis
Amgen INC. $33.95 2023 Repatha, Otezla
Idorsia Pharmaceuticals US INC $31.48 2023 Quviviq
Teva Pharmaceuticals USA, INC. $31.27 2019
Tactile Systems Technology INC $19.43 2023 Entre Plus, Flexitouch Plus
Neurelis, INC. $18.91 2022
Dexcom, INC. $17.05 2023 Dexcom G6 Transmitter
Kowa Pharmaceuticals America, INC. $16.44 2019
Cmp Pharma, INC. $16.40 2022
Exact Sciences Corporation $15.97 2023 Cologuard Collection Kit
Assertio Therapeutics, INC. $12.81 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Warren Groff

$8,127.64

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/161121/warren-groff

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.